

DELIVERED VIA SEDAR

September 12, 2019

Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission

Dear Sirs:

Re: InnoCan Pharma Corporation (the "Corporation") – Final Long Form Prospectus dated September 12, 2019 (the "Final Prospectus")

We refer to the Final Prospectus of the Corporation relating to the issuance of a minimum of 5,055,556 and a maximum of 6,111,112 units of InnoCan Pharma Corporation at a price of CAD0.18 per unit.

We hereby consent to the use of our firm name in the Final Prospectus on the face page of the Final Prospectus and under the headings "Enforcement of Judgements against Foreign Persons", "Experts", and to the use of our opinions under the heading "Eligibility for Investment" in the Final Prospectus.

We confirm we have read the Final Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Final Prospectus that is derived from our opinions referred to therein or that is within our knowledge as a result of services we have performed in connection therewith.

This is a consent contemplated by Section 10.1 of National Instrument 41-101, and to the extent permitted by law we disclaim any liability beyond the statutory liability provisions of Canadian securities legislation applicable to the prospectus.

Yours truly,

BURNET, DUCKWORTH & PALMER LLP
(signed) "Daryl S. Fridhandler"

Daryl S. Fridhandler